Lumasiran sodium

1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

For research use only. We do not sell to patients.

  • Purity: 99.21%
  • CAS No.: 1834612-06-4
  • Molecular Weight:16340 (free acid)
  • Storage:

    -20°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Lumasiran sodium

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00